Tech Company Financing Transactions

Catalyst Biosciences Funding Round

On 12/4/2004, Catalyst Biosciences announced $40 million in Series C funding from EW Healthcare Partners, Sofinnova Ventures and Burrill & Company.

Transaction Overview

Company Name
Catalyst Biosciences
Announced On
12/4/2004
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series C
Investors

EW Healthcare Partners (Lead Investor) (Jeffrey Himawan)

Sofinnova Ventures (Lead Investor) (Barry Selick)

Burrill & Company

HealthCare Ventures

Johnson & Johnson Development Corporation

Morgenthaler Ventures

Novartis BioVenture Fund

Proceeds Purpose
This funding that will allow us to build our pipeline of Alterase therapeutics including advancing our lead protease, CB 813, an improved factor VIIa product for the treatment of acute bleeding in hemophiliacs, through Phase 1/2 proof-of-concept studies in patients.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
611 Gateway Blvd. 710
San Francisco, CA 94080
USA
Phone
(650) 871-0761
Website
www.catalystbiosciences.com
Email Address
[email protected]
Overview
Catalyst is a clinical-stage biopharmaceutical company leveraging exceptional science to discover and develop essential medicines.
Profile
Catalyst Biosciences LinkedIn Company Profile
Social Media
Catalyst Biosciences Company Twitter Account
Company News
Catalyst Biosciences News
Facebook
Catalyst Biosciences on Facebook
YouTube
Catalyst Biosciences on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Nassim Usman
  Nassim Usman LinkedIn Profile  Nassim Usman Twitter Account  Nassim Usman News  Nassim Usman on Facebook
Chief Medical Officer
Howard Levy
  Howard Levy LinkedIn Profile  Howard Levy Twitter Account  Howard Levy News  Howard Levy on Facebook
VP - Bus. Development
Jeffrey Landau
  Jeffrey Landau LinkedIn Profile  Jeffrey Landau Twitter Account  Jeffrey Landau News  Jeffrey Landau on Facebook
VP - Operations
Andrew Hetherington
  Andrew Hetherington LinkedIn Profile  Andrew Hetherington Twitter Account  Andrew Hetherington News  Andrew Hetherington on Facebook

 

 

Browse more venture capital transactions:

Prev: 12/2/2004: Radianse venture capital transaction
Next: 12/6/2004: OVATION Pharmaceuticals venture capital transaction

 

Share this article

 

Where The Data Comes From

Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.